<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Trade</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>US taking a closer look at China biotech subsidies </title>
      <description>
        <![CDATA[U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729320</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729320-us-taking-a-closer-look-at-china-biotech-subsidies</link>
    </item>
    <item>
      <title>US taking a closer look at China biotech subsidies </title>
      <description>
        <![CDATA[U.S. scrutiny of China’s trade practices, especially in the biotech sector, continues to escalate as the U.S. International Trade Commission launches two factfinding investigations Congress mandated in the fiscal 2026 appropriations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729247</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729247-us-taking-a-closer-look-at-china-biotech-subsidies</link>
    </item>
    <item>
      <title>Supreme Court ruling not a death knell for US tariffs </title>
      <description>
        <![CDATA[The ramifications of the U.S. Supreme Court’s decision Feb. 20 that shot down President Donald Trump’s reciprocal tariffs issued under the International Emergency Economic Powers Act are rippling across the world. And Trump’s immediate response to that ruling – a proclamation imposing a temporary 10% import duty on most goods brought into the country beginning Feb. 24 – isn’t helping.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729181</guid>
      <pubDate>Mon, 23 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729181-supreme-court-ruling-not-a-death-knell-for-us-tariffs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/US-tariff-illustration.webp?t=1771885827" type="image/jpeg" medium="image" fileSize="745064">
        <media:title type="plain">US flag, money, global currency symbols, tariff arrow</media:title>
      </media:content>
    </item>
    <item>
      <title>VCs launch coalition to strengthen Europe life sciences investment</title>
      <description>
        <![CDATA[Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729083</guid>
      <pubDate>Fri, 13 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729083-vcs-launch-coalition-to-strengthen-europe-life-sciences-investment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.webp?t=1729025266" type="image/jpeg" medium="image" fileSize="220776">
        <media:title type="plain">Gold Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>VCs launch coalition to strengthen Europe life sciences investment</title>
      <description>
        <![CDATA[Venture capital firms and research institutions have launched the European Life Science Coalition in a bid to strengthen Europe’s VC ecosystem by mobilizing more private and public investment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728861</guid>
      <pubDate>Fri, 13 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728861-vcs-launch-coalition-to-strengthen-europe-life-sciences-investment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-Euro-on-blue-background.webp?t=1729025266" type="image/jpeg" medium="image" fileSize="220776">
        <media:title type="plain">Gold Euro symbol on blue background</media:title>
      </media:content>
    </item>
    <item>
      <title>Trade groups call for EU action on third-party litigation funding</title>
      <description>
        <![CDATA[Third-party litigation funding in Europe has created enough of a stir that several trade associations issued a joint statement making the case that the unregulated nature of these funding agreements is increasing the cost of doing business in a region that is already quite expensive.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728261</guid>
      <pubDate>Wed, 28 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728261-trade-groups-call-for-eu-action-on-third-party-litigation-funding</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/EU-flag-vector.webp?t=1764623220" type="image/jpeg" medium="image" fileSize="108718">
        <media:title type="plain">EU flag vector</media:title>
      </media:content>
    </item>
    <item>
      <title>Advamed says LDT legislation still alive on the Hill</title>
      <description>
        <![CDATA[The U.S. FDA’s final rule for regulation of lab-developed tests is now a part of regulatory litigation history, but Scott Whitaker, CEO and president of the Advanced Medical Technology Association, said that while Congress is still considering LDT legislation, any new legislation may differ substantially from previous bills.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728064</guid>
      <pubDate>Wed, 21 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728064-advamed-says-ldt-legislation-still-alive-on-the-hill</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/US/regulatory-washington-capital.webp?t=1588689711" type="image/png" medium="image" fileSize="560021">
        <media:title type="plain">U.S. Capitol building, Washington D.C.</media:title>
      </media:content>
    </item>
    <item>
      <title>China slashes tariffs on some medical devices</title>
      <description>
        <![CDATA[Beginning Jan. 1, 2026, China will apply provisional import tariff rates lower than the most-favored-nation rates on 935 items, the State Council announced. The move aims to boost collaboration between domestic and international sectors, and to leverage resources of both to expand the supply of high-quality goods.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727603</guid>
      <pubDate>Fri, 09 Jan 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727603-china-slashes-tariffs-on-some-medical-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/Globe-and-China-flag.webp?t=1766436912" type="image/jpeg" medium="image" fileSize="571448">
        <media:title type="plain">Globe and China flag</media:title>
      </media:content>
    </item>
    <item>
      <title>US, South Korea trade deal eases industry’s pharma tariff fears</title>
      <description>
        <![CDATA[The Korea Biotechnology Industry Organization on Oct. 30 welcomed the bilateral trade deal between the U.S. and South Korea announced during U.S. President Donald Trump’s state visit alongside the Asia-Pacific Economic Cooperation forum in Gyeongju, South Korea.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725690</guid>
      <pubDate>Thu, 30 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725690-us-south-korea-trade-deal-eases-industrys-pharma-tariff-fears</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Donald-Trump-and-Lee-Jae-myung-10-30.webp?t=1761848731" type="image/jpeg" medium="image" fileSize="595818">
        <media:title type="plain">U.S. President Donald J. Trump (left) and South Korea President Lee Jae-myung at the ROK-U.S. summit</media:title>
        <media:description type="plain">U.S. President Donald J. Trump (left) and South Korea President Lee Jae-myung at the ROK-U.S. summit in Gyeongju-si, South Korea Oct. 29. Source: Office of the President Republic of Korea</media:description>
      </media:content>
    </item>
    <item>
      <title>Trump hits drug imports with 100% tariffs, starting Oct. 1</title>
      <description>
        <![CDATA[The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% import duty will apply beginning Oct. 1. However, the flurry of recent announcements by pharma companies of investments in U.S. manufacturing plants may have paid off, with the president saying in his announcement on Truth Social that the 100% rate will be enforced “unless a company is building their manufacturing plant in America.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/724742</guid>
      <pubDate>Tue, 30 Sep 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724742-trump-hits-drug-imports-with-100-tariffs-starting-oct-1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/100-percentage-illustration.webp?t=1758909807" type="image/jpeg" medium="image" fileSize="367958">
        <media:title type="plain">100 percentage illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Trump hits drug imports with 100% tariffs, starting Oct. 1</title>
      <description>
        <![CDATA[The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% import duty will apply beginning Oct. 1. However, the flurry of recent announcements by pharma companies of investments in U.S. manufacturing plants may have paid off, with the president saying in his announcement on Truth Social that the 100% rate will be enforced “unless a company is building their manufacturing plant in America.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/724670</guid>
      <pubDate>Fri, 26 Sep 2025 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724670-trump-hits-drug-imports-with-100-tariffs-starting-oct-1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/100-percentage-illustration.webp?t=1758909807" type="image/jpeg" medium="image" fileSize="367958">
        <media:title type="plain">100 percentage illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>US expands tariff investigations into med tech, robotics, diagnostics</title>
      <description>
        <![CDATA[The Trump administration has launched an investigation into the national security effects of imports of medical equipment, devices, consumables and equipment, laying the groundwork for a potential increase in tariffs targeting the industry. A separate investigation into robotics and industrial machinery began the same day. Med-tech stocks dropped significantly in response to the news as investors fear increased tariffs on the sector. In April, the administration initiated a similar review of the pharmaceutical industry and in August threatened 200% tariffs on that sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724243</guid>
      <pubDate>Thu, 25 Sep 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724243-us-expands-tariff-investigations-into-med-tech-robotics-diagnostics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Europe/Europe-US-Tariffs-Trade-Map.webp?t=1755812059" type="image/jpeg" medium="image" fileSize="893216">
        <media:title type="plain">Wooden blocks spelling TARIFFS with a U.S. flag on top, placed on a map of Europe</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea pharma group to support exports, Korea-Japan-China trade</title>
      <description>
        <![CDATA[The Korea Pharmaceutical Traders Association said Aug. 26 that it signed a strategic agreement with Korea Trade Insurance Corp. to support South Korean companies exporting biopharmaceutical materials overseas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723866</guid>
      <pubDate>Tue, 02 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723866-korea-pharma-group-to-support-exports-korea-japan-china-trade</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-trade-KTPA-K-Sure-8-29.webp?t=1756492732" type="image/jpeg" medium="image" fileSize="383461">
        <media:title type="plain">K-Sure Chairman and President Jang Young-jin Ryu (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing</media:title>
        <media:description type="plain">K-Sure Chairman and President Jang Young-jin (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing at K-Sure headquarters in Seoul, South Korea Aug. 26.</media:description>
      </media:content>
    </item>
    <item>
      <title>Korea pharma group to support exports, Korea-Japan-China trade</title>
      <description>
        <![CDATA[The Korea Pharmaceutical Traders Association said Aug. 26 that it signed a strategic agreement with Korea Trade Insurance Corp. to support South Korean companies exporting biopharmaceutical materials overseas.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723648</guid>
      <pubDate>Fri, 29 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723648-korea-pharma-group-to-support-exports-korea-japan-china-trade</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-trade-KTPA-K-Sure-8-29.webp?t=1756492732" type="image/jpeg" medium="image" fileSize="383461">
        <media:title type="plain">K-Sure Chairman and President Jang Young-jin Ryu (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing</media:title>
        <media:description type="plain">K-Sure Chairman and President Jang Young-jin (right) with KPTA Chairman Ryu Hyung-seon at the MOU signing at K-Sure headquarters in Seoul, South Korea Aug. 26.</media:description>
      </media:content>
    </item>
    <item>
      <title>South Korea hits record $23B pharma production; 2024 exports up 28% </title>
      <description>
        <![CDATA[South Korea’s pharmaceutical manufacturing reached an all-time high of ₩32.86 trillion (US$23 billion) in 2024, representing a 7.3% increase from 2023 and the highest on record since the country began count in 1998.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722712</guid>
      <pubDate>Tue, 29 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722712-south-korea-hits-record-23b-pharma-production-2024-exports-up-28</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-manufacturing.webp?t=1588350006" type="image/png" medium="image" fileSize="429133">
        <media:title type="plain">Tablets on conveyor belt</media:title>
      </media:content>
    </item>
    <item>
      <title>South Korea hits record $23B pharma production; 2024 exports up 28% </title>
      <description>
        <![CDATA[South Korea’s pharmaceutical manufacturing reached an all-time high of ₩32.86 trillion (US$23 billion) in 2024, representing a 7.3% increase from 2023 and the highest on record since the country began count in 1998.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722424</guid>
      <pubDate>Thu, 24 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722424-south-korea-hits-record-23b-pharma-production-2024-exports-up-28</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-manufacturing.webp?t=1588350006" type="image/png" medium="image" fileSize="429133">
        <media:title type="plain">Tablets on conveyor belt</media:title>
      </media:content>
    </item>
    <item>
      <title>Rx tariffs a few weeks away?</title>
      <description>
        <![CDATA[“Pharmaceuticals will be tariffed, probably at the end of the month,” U.S. President Donald Trump said, as he provided a few more details about his proposed global biopharma sector tariff. “We’re going to start off with a low tariff and give the pharmaceutical companies a year or so to build. And then we’re going to make it a very high tariff.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/722163</guid>
      <pubDate>Wed, 16 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722163-rx-tariffs-a-few-weeks-away</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Prescription-drug-bottles-and-pills.webp?t=1623264455" type="image/png" medium="image" fileSize="297425">
        <media:title type="plain">Prescription drug bottles and pills</media:title>
      </media:content>
    </item>
    <item>
      <title>Optimism prevails despite talk of 200% biopharma tariff</title>
      <description>
        <![CDATA[The U.S. Commerce Department isn't expected to complete its Section 232 investigation to build a national security case for imposing tariffs on biopharmaceuticals until the end of the month, but that didn’t stop President Donald Trump from once again teasing a “very, very high” tariff for medicines and their ingredients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721924</guid>
      <pubDate>Wed, 09 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721924-optimism-prevails-despite-talk-of-200-biopharma-tariff</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Pills-bottle-on-100-bills.webp?t=1744839445" type="image/jpeg" medium="image" fileSize="176555">
        <media:title type="plain">Pills, bottle on $100 bills</media:title>
      </media:content>
    </item>
    <item>
      <title>ABPI: UK’s rebate rates ‘send a terrible message’ to global investors</title>
      <description>
        <![CDATA[The U.K. government has doubled the rate that pharmaceutical companies must repay on sales of branded drugs, under the statutory rebate scheme, to a record 31.3%. Only 1-2% of total sales of branded drugs fall under the statutory scheme, but the increase is seen as a sign that an ongoing review of the voluntary scheme is not going well.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721017</guid>
      <pubDate>Wed, 11 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721017-abpi-uks-rebate-rates-send-a-terrible-message-to-global-investors</link>
    </item>
    <item>
      <title>European Commission clamps down on Chinese med tech</title>
      <description>
        <![CDATA[The trade wars spanning the globe lined up some unlikely-seeming adversaries, and such is the case in the trade scrum between the EU and China.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720761</guid>
      <pubDate>Tue, 10 Jun 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720761-european-commission-clamps-down-on-chinese-med-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-export-trade.webp?t=1591828115" type="image/png" medium="image" fileSize="1264029">
        <media:title type="plain">Shipping container with flag of China</media:title>
      </media:content>
    </item>
    <item>
      <title>Korea pharma exports rise to quarterly high of $2.5B in Q1</title>
      <description>
        <![CDATA[South Korea’s pharmaceutical exports rose nearly 18% year-on-year to reach $2.56 billion in the first quarter (Q1) this year, according to the Korea Health Industry Development Institute. Medical device exports, however, dropped about 5% in Q1 2025 to $1.39 billion, attributed to a drop in trade of implant products to both China and the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721155</guid>
      <pubDate>Tue, 10 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721155-korea-pharma-exports-rise-to-quarterly-high-of-25b-in-q1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/South-Korea-flag-business.webp?t=1706306564" type="image/jpeg" medium="image" fileSize="140130">
        <media:title type="plain">Flag of South Korea with skyscrapers in the background </media:title>
      </media:content>
    </item>
    <item>
      <title>MHRA offers clarity for bacteriophage development, licensing</title>
      <description>
        <![CDATA[The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has issued its first official guidance on how to develop bacteriophages as licensed medicinal products. This covers personalized phage therapies designed for specific patients – at present the only form in which they are available – but also is relevant to the development of off-the-shelf products for treating common infections.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720986</guid>
      <pubDate>Mon, 09 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720986-mhra-offers-clarity-for-bacteriophage-development-licensing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Bacteriophage.webp?t=1704817295" type="image/jpeg" medium="image" fileSize="232612">
        <media:title type="plain">3D illustration of phage infecting bacteria</media:title>
      </media:content>
    </item>
    <item>
      <title>EMA: New clinical guideline includes pregnant, breastfeeding patients </title>
      <description>
        <![CDATA[The EMA has issued a new guideline on how to include and/or retain pregnant and breastfeeding women in clinical trials, in a move that it says “marks a change in the paradigm.” The aim is to ensure that trial sponsors generate robust clinical data in these populations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720938</guid>
      <pubDate>Thu, 05 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720938-ema-new-clinical-guideline-includes-pregnant-breastfeeding-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/Pregnant-woman-profile.webp?t=1668724885" type="image/png" medium="image" fileSize="200833">
        <media:title type="plain">Pregnant woman </media:title>
      </media:content>
    </item>
    <item>
      <title>Korea pharma exports rise to quarterly high of $2.5B in Q1</title>
      <description>
        <![CDATA[South Korea’s pharmaceutical exports rose nearly 18% year-on-year to reach $2.56 billion in the first quarter (Q1) this year, according to the Korea Health Industry Development Institute. Medical device exports, however, dropped about 5% in Q1 2025 to $1.39 billion, attributed to a drop in trade of implant products to both China and the U.S.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720892</guid>
      <pubDate>Wed, 04 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720892-korea-pharma-exports-rise-to-quarterly-high-of-25b-in-q1</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/South-Korea-flag-business.webp?t=1706306564" type="image/jpeg" medium="image" fileSize="140130">
        <media:title type="plain">Flag of South Korea with skyscrapers in the background </media:title>
      </media:content>
    </item>
    <item>
      <title>US trade court blocks emergency tariffs, but threat remains</title>
      <description>
        <![CDATA[A court decision blocking President Donald Trump’s reciprocal and trafficking tariffs was hardly a day old before the U.S. Court of Appeals for the Federal Circuit stepped in late May 29 to grant a temporary stay while it considers the administration’s appeal. The stay adds further uncertainty to the path ahead for drug and device companies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720596</guid>
      <pubDate>Thu, 29 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720596-us-trade-court-blocks-emergency-tariffs-but-threat-remains</link>
    </item>
    <item>
      <title>USTR begins search for biopharma R&amp;D ‘freeloaders’</title>
      <description>
        <![CDATA[The U.S. Trade Representative (USTR) is asking for help in its search for “freeloaders” that refuse to shoulder their share of the cost of biopharma R&D.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720507</guid>
      <pubDate>Wed, 28 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720507-ustr-begins-search-for-biopharma-r-and-d-freeloaders</link>
    </item>
    <item>
      <title>South Korea urges US to exempt pharma, allies from tariffs</title>
      <description>
        <![CDATA[South Korean government and biopharmaceutical industry representatives urged American policymakers May 7 to refrain from imposing tariffs on pharmaceutical imports, and to spare allies if pharma tariffs are deemed necessary. Both Korea’s Ministry of Health and Welfare on May 4 and the Korea Biotechnology Industry Organization on May 6 submitted comments to the U.S. Department of Commerce in response to its ongoing investigation of pharmaceutical imports.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720205</guid>
      <pubDate>Tue, 13 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720205-south-korea-urges-us-to-exempt-pharma-allies-from-tariffs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Trump-tariff-signing-5-7.webp?t=1746651209" type="image/jpeg" medium="image" fileSize="226035">
        <media:title type="plain">Trump tariff EO signing </media:title>
        <media:description type="plain">U.S. President Donald Trump at a signing ceremony of an executive order on tariffs at the White House April 2, 2025. </media:description>
      </media:content>
    </item>
    <item>
      <title>US legal issues to track in pharma, biotech</title>
      <description>
        <![CDATA[Ongoing policy issues in the U.S., including the Inflation Reduction Act and recent proposals under President Donald Trump’s administration, have wide ranging implications for the global biopharmaceutical industry, speakers at Bio Korea 2025 said May 8, including a heightened need for all biotechs to draft regulatory strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720200</guid>
      <pubDate>Tue, 13 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720200-us-legal-issues-to-track-in-pharma-biotech</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Jorge-Goldstein-at-BioKorea-5-8.webp?t=1746734985" type="image/jpeg" medium="image" fileSize="272720">
        <media:title type="plain">Jorge A. Goldstein at Bio Korea 2025</media:title>
        <media:description type="plain">Jorge A. Goldstein of Sterne, Kessler, Goldstein and Fox PLLC presents on the IRA and U.S. policy implications at Bio Korea 2025 May 8 in Seoul, South Korea.</media:description>
      </media:content>
    </item>
    <item>
      <title>Korea pharma stocks rally; Celltrion welcomes US drug pricing</title>
      <description>
        <![CDATA[Korean pharmaceutical stocks rose across the board May 13, a day after U.S. President Donald Trump signed off on the most favored nation executive order, a drug pricing policy expected to benefit biosimilar makers in the U.S., according to Celltrion Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720109</guid>
      <pubDate>Tue, 13 May 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720109-korea-pharma-stocks-rally-celltrion-welcomes-us-drug-pricing</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/south-korea-won-financing.webp?t=1614968120" type="image/png" medium="image" fileSize="258184">
        <media:title type="plain">Illustration of Won currency, graph, up arrows</media:title>
      </media:content>
    </item>
    <item>
      <title>Little bite from voluntary most-favored nation Rx pricing order </title>
      <description>
        <![CDATA[After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite, as one analyst put it. Brian Abrahams, head of global healthcare research at RBC Capital Markets LLC, said the EO is unlikely to rattle the biopharma sector, even though it lacked the certainty to completely remove the MFN overhang. “We see reason for relief and, alongside improving FDA clarity and limited tariff risk, expect biopharma to be viewed as increasingly investable,” Abrahams said.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720151</guid>
      <pubDate>Mon, 12 May 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720151-little-bite-from-voluntary-most-favored-nation-rx-pricing-order</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Drug-capsule-and-dollar-sign.webp?t=1617651432" type="image/png" medium="image" fileSize="186891">
        <media:title type="plain">Drug capsule and dollar sign</media:title>
      </media:content>
    </item>
  </channel>
</rss>
